J&J resumes US rollout of single-dose COVID-19 vaccine
CDC and FDA recommended pause be lifted after ‘rigorous review’ of very rare blood clots
Rollout of Johnsons & Johnson’s (J&J) COVID-19 vaccine is primed to resume in the US after the US Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) recommended lifting the temporary pause on the jab.
The CDC and FDA recommended the pause following six reported cases in the US of a rare and severe type of blood clot – known as cerebral venous sinus thrombosis (CVST) – observed in individuals after receiving the single-dose J&J vaccine.
J&J COVID-19 vaccine hold lifted in the US pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW BRUNSWICK, N.J., April 23, 2021 /PRNewswire/ Johnson & Johnson (NYSE: JNJ) (the Company) today announced that vaccinations with the Company s COVID-19 single-shot vaccine will resume for all adults aged 18 years and older in the U.S., under Emergency Use Authorization (EUA), following a decision from the United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA).
The decision was based on a recommendation from the U.S. CDC Advisory Committee on Immunization Practices (ACIP), which followed a rigorous evaluation of data relating to a very rare adverse event involving blood clots in combination with low platelet counts (thrombosis with thrombocytopenia) observed within approximately one to two weeks following vaccination.
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U S for All Adults Aged 18 and Older Following CDC and FDA Decision investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Pharma Stock Roundup: JNJ s Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates Zacks.com 2 hrs ago J&J JNJ announced strong first-quarter results, beating estimates for both earnings and sales.
Roche’s RHHBY COVID-19 diagnostics tests sales boosted the top line, offsetting declines in its core drug business. The FDA granted approval to
Glaxo’s GSK endometrial cancer therapy, Jemperli (dostarlimab).
Recap of the Week’s Most Important Stories
J&J Earnings & Sales Beat: J&J beat first-quarter estimates for earnings as well as sales. Its Pharmaceuticals unit continued to perform above market levels while the recovery in the Medical Devices unit continued. However, unfavorable comparisons to the year-ago quarter due to COVID-19 pantry loading and demand surges experienced in 2020 hurt sales of the Consumer Health segment in the first quarter of 2021